Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2- yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 8, 2012, Pages 2837-2842

  Han, Sun Young ^a,b   Choi, Jie Won ^a,c   Yang, Jeon ^a,d   Chae, Chong Hack ^a   Lee, Jongkook ^a   Jung, Heejung ^a   Lee, Kwangho ^a   Ha, Jae Du ^a   Kim, Hyoung Rae ^a   Cho, Sung Yun ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Sogang University   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

Cancer; Imidazo 4,5 c pyridine; KDR kinase; Quinolin 2 one; VEGFR 2

Indexed keywords

3 (4,5,6,7 TETRAHYDRO 3H IMIDAZO[4,5 C]PYRIDIN 2 YL) 1H QUINOLIN 2 ONE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; REACTION ANALYSIS;

CELL PROLIFERATION; CELLS, CULTURED; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84862783839     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.02.073     Document Type: Article

References (37)

1. A.K. Olsson, A. Kimberg, J. Kreuger, and L. Claesson-Welsh Nat. Rev. Mol. Cell Biol. 7 2006 359
2. N. Ferrara, H. Gerber, and J. LeCouter Nat. Med. 9 2003 669
3. P. Carmeliet Nat. Med. 9 2003 653 660
4. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg N. Eng. J. Med. 349 2003 427
5. N. Ferrara, H. Gerber, and J. LeCouter Nat. Med. 6 2003 669
6. M.J. Cross, and L. Claesson-Welsh Trends Pharmacol. Sci. 22 2001 201
7. G. McMahon Oncologist 5 2000 3
8. M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, P. Bohlen, and D.J. Hicklin Cancer Res. 59 1999 5209
9. M.H. Cohen, J. Gootenberg, P. Keegan, and R. Pazdur Oncologist 12 2007 356
10. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, and D.H. Johnson N. Eng. J. Med. 355 2006 2542
11. A.R. Cardones, and L.L. Banez Curr. Pharm. Des. 12 2006 387
12. S.J. Boyer Curr. Top. Med. Chem. 2 2002 973
13. P. Traxler Expert Opin. Ther. Targets 2 2003 215
14. M. Atkins, C.A. Jones, and P. Kirkpatrick Nat. Rev. Drug Disc. 5 4 2006 279 280
15. D. Strumberg Drugs Today 41 2005 773
16. R. Ng, and E.X. Chen Curr. Clin. Pharmacol. 1 2006 223 228
17. L.S. Rosen, R. Kurzrock, M. Mulay, A. Van Vugt, M. Purdom, C. Ng, J. Silverman, A. Koutsoukos, Y.-N. Sun, M.B. Bass, R.Y. Xu, A. Polverino, J.S. Wiezorek, D.D. Chang, R. Benjamin, and R.S. Herbst J. Clin. Oncol. 25 17 2007 2369
18. J. Harmange, M. Weiss, J. Germain, A.J. Polverino, G. Borg, J. Bready, W. Buckner, D. Chen, D. Choquette, A. Coxon, T. DeMelfi, L. DiPietro, N. Doerr, J. Estrada, I. Fellows, J. Flynn, R.F. Graceffa, S.P. Harriman, S. Kaufman, D.S. La, A. Long, M.W. Martin, S. Neervannan, V.F. Patel, M. Potashman, K. Regal, P.M. Roveto, M.L. Schrag, C. Starnes, A. Tasker, Y. Teffera, L. Wang, R.D. White, D. Whittington, and R. Zanon J. Med. Chem. 51 2008 1649
19. M.M. Weiss, J. Harmange, A.J. Polverino, D. Bauer, L. Berry, V. Berry, G. Borg, J. Bready, A. Bretz, D. Chen, V. Chi, D. Choquette, A. Coxon, T. DeMelfi, N. Doerr, J. Estrada, I. Fellows, J. Flynn, R.F. Graceffa, S.P. Harriman, S. Kaufman, D.S. La, A. Long, S. Neervannan, V.F. Patel, M. Potashman, K. Regal, P.M. Roveto, M.L. Schrag, C. Starnes, A. Tasker, Y. Teffera, D. Whittington, and R. Zanon J. Med. Chem. 51 2008 1668 1680
20. D. Mendel, D. Laird, X. Xin, S. Louie, J. Christensen, G. Li, R. Schreck, T. Abrams, T. Ngai, L. Lee, L. Murray, J. Carver, E. Chan, K. Moss, J. Haznedar, J. Sukbuntherng, R. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, and J. Cherrington Clin. Cancer Res. 9 2003 327
21. P.A. Renhowe, S. Pecchi, C.M. Shafer, T.D. Machajewski, E.M. Jazan, C. Taylor, W. Antonios-McCrea, C.M. McBride, K. Frazier, M. Wiesmann, G.R. Lapointe, P.H. Feucht, R.L. Warne, C.C. Heise, D. Menezes, K. Aardalen, H. Ye, M. He, V. Le, J. Vora, J.M. Jansen, M.E. Wernette-Hammond, and A.L. Harris J. Med. Chem. 52 2009 278
22. M.E. Fraley, K.L. Arrington, C.A. Buser, P.A. Ciecko, K.E. Coll, C. Fernandes, G.D. Hartman, W.F. Hoffman, J.J. Lynch, R.C. McFall, K. Rickert, R. Singh, S. Smith, K.A. Thomas, and B.K. Wong Bioorg. Med. Chem. Lett. 14 2004 351
23. P.W. Neber, A. Burgard, and W. Their Ann. Chem. 1 1936 277
24. J.L. LaMattina, and R.T. Suleske Synthesis 1 1980 329
25. J.L. LaMattina, and R.T. Sulske Org. Synth. 64 1986 19
26. K. Itoh, and Y. Oka Chem. Pharm. Bull. 2016 1983 31
27. A. Diez, A. Voldoire, I. Lopez, M. Rubiralta, V. Segarra, L. Pages, and J.M. Palacios Tetrahedron 51 1995 5143
28. J.D. Ha, S.J. Lee, S.Y. Nam, S.K. Kang, S.Y. Cho, J.H. Ahn, and J.-K. Choi Tetrahedron Lett. 47 2006 6201
29. For the reaction between 2-benzoimidazole-2-ylacetate and 2-aminobenzaldehyde: Fraley, M. E.; Hambaugh, S. R.; Hungate, R. W. U.S. Patent 6479512 B1, 2002.
30. 50 using Prism version 5.01 (GraphPad).
31. 50 values were estimated using Prism Software.
32. Microsomal stability test: NADPH dependent oxidative metabolism of 21 in human and rat liver microsomes was determined on single-time-point 30 min. The reaction mixtures consisted of human or rat liver microsomes (0.5 mg/ml; BD Gentest) in 100 mM potassium phosphate buffer (pH 7.4) and final concentration of 21 was 2 μM. After pre-incubation of reaction mixture at 37 °C for 5 min, the reaction was initiated by addition NADPH regeneration solution (BD Biosciences) and the reaction was terminated by adding three times volume of ice-cold acetonitrile with imipramine (80 ng/ml) as internal standard at single-time-point 30 min. After pretreatment of biological samples with vortex and centrifuging, the samples were analyzed by LC/MS/MS system (AB Sciex 2000 Qtrap).
33. G. Ottaviani, S. Martel, and P.-A. Carrupt J. Med. Chem. 49 2006 3948
34. In vitro VEGF-induced HUVEC proliferation assay: Pooled HUVECs (Lonza) were grown in a 1:1 mixture of EBM-2 medium with EGM-2 supplements and used at passage eight or lower. HUVECs were placed at a density of 10,000 cells/well on a collagen type I precoated 96-well plate. After 24 h, the cells were incubated for 24 h in the presence of rhVEGF (20 ng/mL) in the presence of the compound under examination. Cells were assayed for proliferation by the Premix WST-1 proliferation assay system (Takara).
35. In vitro angiogenesis assay (tube formation): 24-well plates were coated with 200 mL of a 1:1 mixture of Matrigel (10 mg/mL) and EBM-2 medium with EGM-2 supplements and incubated at 37 °C for 1 h. HUVECs (Lonza) were placed at a density of 40,000/well and incubated for 16-18 h. After incubation, the plates were fixed and images were captured using a Nikon camera (50×) and analyzed using Image-Pro Plus software (Media Cybernetics).
36. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, and D.T. Mainz J. Med. Chem. 47 2004 1739
37. K.S. Gajiwala, J.C. Wu, J. Christensen, G.D. Deshmukh, W. Diehl, J.P. DiNitto, J.M. English, M.J. Greig, Y.A. He, S.L. Jacques, E.A. Lunney, M. McTigue, D. Molina, T. Quenzer, P.A. Wells, X. Yu, Y. Zhang, A. Zou, M.R. Emmett, A.G. Marshall, H.M. Zhang, and G.D. Demetri Proc. Natl. Acad. Sci. U.S.A. 106 2009 1542